SUSAN BLANEY

TitleProfessor
InstitutionBaylor College of Medicine
DepartmentDepartment of Pediatrics
Address1102 BATES
Houston, TX 77030
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Faculty Mentor
    Collapse Verify Publications

    Collapse Overview 
    Collapse overview
    Susan M. Blaney, M.D. is the Elise C. Young Chair in Pediatrics and a Professor in the Department of Pediatrics at Baylor College of Medicine. She serves as the Director of Texas Children's Cancer and Hematology Centers at Texas Children's Hospital. She has extensive experience in clinical and translational research with a focus on the development of new treatment strategies for children with brain tumors and other refractory cancers. In the past, she served as the Vice President for Clinical and Translational Research at BCM, Executive Vice Chair of the Department of Pediatrics, Vice Chair for the Children’s Oncology Group, an international clinical trial cooperative group supported by the National Cancer Institute (NCI), Chair of the NCI's Pediatric Phase 1 and Pilot Consortium. She has served on the Clinical Trial Advisory Committee for the National Cancer Institute and as a consultant of the FDA’s pediatric Oncology Drug Advisory Committee.

    Collapse Research 
    Collapse research activities and funding
    R55CA075554     (BLANEY, SUSAN M)Sep 15, 1997 - Sep 14, 1999
    NIH/NCI
    PHENYLBUTYRATE--CLINICAL TRIALS IN PEDIATRIC CANCER
    Role: Principal Investigator

    U01CA081465     (BLANEY, SUSAN M)Apr 1, 1999 - Mar 31, 2004
    NIH/NCI
    PEDIATRIC BRAIN TUMOR RESEARCH CENTER
    Role: Principal Investigator

    R21CA082744     (BLANEY, SUSAN M)Sep 15, 1999 - Sep 14, 2001
    NIH/NCI
    PHENYLBUTYRATE--PHASE II PEDIATRIC TRIAL FOR CNS TUMORS
    Role: Principal Investigator

    K12CA090433     (BLANEY, SUSAN M.)Jul 1, 2002 - Jun 30, 2022
    NIH/NCI
    Pediatric Oncology Clinical Research Training Program
    Role: Principal Investigator

    U01CA097452     (BLANEY, SUSAN M)Aug 8, 2002 - Sep 29, 2012
    NIH/NCI
    Children's Oncology Group Phase 1 / Pilot Consortium
    Role: Principal Investigator

    UM1CA097452     (WEIGEL, BRENDA J.)Aug 8, 2002 - Sep 30, 2018
    NIH/NCI
    Pediatric Phase 1/Pilot Consortium
    Role: Co-Principal Investigator

    U10CA180886     (APLENC, RICHARD)Apr 11, 2014 - Feb 28, 2025
    NIH/NCI
    COG NCTN Network Group Operations Center
    Role: Co-Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Greengard E, Mosse YP, Liu X, Minard CG, Reid JM, Voss S, Wilner K, Fox E, Balis F, Blaney SM, Adamson PC, Weigel BJ. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212). Cancer Chemother Pharmacol. 2020 Dec; 86(6):829-840. PMID: 33095287.
      Citations:    Fields:    
    2. Baxter PA, Su JM, Onar-Thomas A, Billups CA, Li XN, Poussaint TY, Smith ER, Thompson P, Adesina A, Ansell P, Giranda V, Paulino A, Kilburn L, Quaddoumi I, Broniscer A, Blaney SM, Dunkel IJ, Fouladi M. A phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2020 06 09; 22(6):875-885. PMID: 32009149.
      Citations: 1     Fields:    
    3. Su JM, Murray JC, McNall-Knapp RY, Bowers DC, Shah S, Adesina AM, Paulino AC, Jo E, Mo Q, Baxter PA, Blaney SM. A phase 2 study of valproic acid and radiation, followed by maintenance valproic acid and bevacizumab in children with newly diagnosed diffuse intrinsic pontine glioma or high-grade glioma. Pediatr Blood Cancer. 2020 06; 67(6):e28283. PMID: 32285998.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    4. Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR, Romero JC, Hicks MJ, Nelson MD, Voss S, Reid JM, Fox E, Weigel BJ, Blaney SM. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer. 2020 02; 67(2):e28073. PMID: 31724813.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    5. Mossé YP, Fox E, Teachey DT, Reid JM, Safgren SL, Carol H, Lock RB, Houghton PJ, Smith MA, Hall D, Barkauskas DA, Krailo M, Voss SD, Berg SL, Blaney SM, Weigel BJ. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238. PMID: 30777875.
      Citations: 5     Fields:    Translation:HumansAnimalsCTClinical Trials
    6. Blaney SM. Editorial: Recent advances in pediatric oncology. Curr Opin Pediatr. 2019 02; 31(1):1-2. PMID: 30614919.
      Citations:    Fields:    Translation:Humans
    7. Bertagnolli MM, Blaney SM, Blanke CD, Curran WJ, Dancey J, Mannel RS, O'Dwyer PJ, Schnall MD, Wolmark N. Current Activities of the Coalition of Cancer Cooperative Groups. J Natl Cancer Inst. 2019 01 01; 111(1):11-18. PMID: 30544145.
      Citations:    Fields:    Translation:Humans
    8. Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, Horton TM, Bush R, Blaney SM, Weigel BJ, Kelly KM. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018 09; 19(9):1229-1238. PMID: 30122620.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    9. Schafer ES, Rau RE, Berg S, Liu X, Minard CG, D'Adamo D, Scott R, Reyderman L, Martinez G, Devarajan S, Reid JM, Fox E, Weigel BJ, Blaney SM. A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer. 2018 08; 65(8):e27066. PMID: 29719113.
      Citations: 4     Fields:    Translation:HumansCellsCTClinical Trials
    10. Chuk MK, Widemann BC, Minard CG, Liu X, Kim A, Bernhardt MB, Kudgus RA, Reid JM, Voss SD, Blaney S, Fox E, Weigel BJ. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 08; 65(8):e27077. PMID: 29693796.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    11. Blaney SM. Recent advances in pediatric oncology. Curr Opin Pediatr. 2018 02; 30(1):1-2. PMID: 29176358.
      Citations:    Fields:    Translation:Humans
    12. Rau RE, Dreyer Z, Choi MR, Liang W, Skowronski R, Allamneni KP, Devidas M, Raetz EA, Adamson PC, Blaney SM, Loh ML, Hunger SP. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 03; 65(3). PMID: 29090524.
      Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
    13. Kilburn LB, Kocak M, Baxter P, Poussaint TY, Paulino AC, McIntyre C, Lemenuel-Diot A, Lopez-Diaz C, Kun L, Chintagumpala M, Su JM, Broniscer A, Baker JN, Hwang EI, Fouladi M, Boyett JM, Blaney SM. A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. Pediatr Blood Cancer. 2018 Feb; 65(2). PMID: 29090526.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    14. Mossé YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, Adamson P, Wilner K, Blaney SM, Weigel BJ. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 01; 35(28):3215-3221. PMID: 28787259.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    15. Leary SES, Park JR, Reid JM, Ralya AT, Baruchel S, Wu B, Roberts TPL, Liu X, Minard CG, Fox E, Weigel B, Blaney S. Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2017 Oct 15; 23(20):6062-6069. PMID: 28751444.
      Citations: 1     Fields:    Translation:Humans
    16. Geller JI, Perentesis JP, Liu X, Minard CG, Kudgus RA, Reid JM, Fox E, Blaney SM, Weigel BJ. A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11). PMID: 28449393.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    17. Rheingold SR, Tasian SK, Whitlock JA, Teachey DT, Borowitz MJ, Liu X, Minard CG, Fox E, Weigel BJ, Blaney SM. A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114). Br J Haematol. 2017 05; 177(3):467-474. PMID: 28295182.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    18. Heikamp EB, Blaney SM. 50 Years Ago in The Journal of Pediatrics: Diencephalic Syndromes of Infancy: Report of 3 Children with Emaciation Syndrome and Disproportionately Large Hands and Feet. J Pediatr. 2017 03; 182:113. PMID: 28237444.
      Citations:    Fields:    Translation:Humans
    19. Balis FM, Thompson PA, Mosse YP, Blaney SM, Minard CG, Weigel BJ, Fox E. First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium. Cancer Chemother Pharmacol. 2017 Jan; 79(1):181-187. PMID: 28032129.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    20. Lagmay JP, Krailo MD, Dang H, Kim A, Hawkins DS, Beaty O, Widemann BC, Zwerdling T, Bomgaars L, Langevin AM, Grier HE, Weigel B, Blaney SM, Gorlick R, Janeway KA. Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016 09 01; 34(25):3031-8. PMID: 27400942.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    21. Blaney SM, Adamson PC, Wechsler DS. The 2016 ASPHO Distinguished Career Award Goes to David G. Poplack, MD. Pediatr Blood Cancer. 2016 Jun; 63 Suppl 1:S5-6. PMID: 27077669.
      Citations:    Fields:    
    22. Wetmore C, Daryani VM, Billups CA, Boyett JM, Leary S, Tanos R, Goldsmith KC, Stewart CF, Blaney SM, Gajjar A. Phase II evaluation of sunitinib in the treatment of recurrent or refractory high-grade glioma or ependymoma in children: a children's Oncology Group Study ACNS1021. Cancer Med. 2016 07; 5(7):1416-24. PMID: 27109549.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    23. Loh ML, Tasian SK, Rabin KR, Brown P, Magoon D, Reid JM, Chen X, Ahern CH, Weigel BJ, Blaney SM. A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011). Pediatr Blood Cancer. 2015 Oct; 62(10):1717-24. PMID: 25976292.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    24. Hoffman LM, Fouladi M, Olson J, Daryani VM, Stewart CF, Wetmore C, Kocak M, Onar-Thomas A, Wagner L, Gururangan S, Packer RJ, Blaney SM, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study. Childs Nerv Syst. 2015 Aug; 31(8):1283-9. PMID: 25930724.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    25. Kim A, Widemann BC, Krailo M, Jayaprakash N, Fox E, Weigel B, Blaney SM. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Sep; 62(9):1562-6. PMID: 26207356.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    26. Kolb EA, Sampson V, Stabley D, Walter A, Sol-Church K, Cripe T, Hingorani P, Ahern CH, Weigel BJ, Zwiebel J, Blaney SM. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report. Pediatr Blood Cancer. 2015 May; 62(5):751-8. PMID: 25728527.
      Citations: 13     Fields:    Translation:HumansCellsCTClinical Trials
    27. Fouladi M, Perentesis JP, Wagner LM, Vinks AA, Reid JM, Ahern C, Thomas G, Mercer CA, Krueger DA, Houghton PJ, Doyle LA, Chen H, Weigel B, Blaney SM. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. Clin Cancer Res. 2015 Apr 01; 21(7):1558-65. PMID: 25467181.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    28. Wagner LM, Fouladi M, Ahmed A, Krailo MD, Weigel B, DuBois SG, Doyle LA, Chen H, Blaney SM. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2015 Mar; 62(3):440-4. PMID: 25446280.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    29. Kilburn LB, Kocak M, Decker RL, Wetmore C, Chintagumpala M, Su J, Goldman S, Banerjee A, Gilbertson R, Fouladi M, Kun L, Boyett JM, Blaney SM. A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11. PMID: 25431212.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    30. Burke MJ, Ahern C, Weigel BJ, Poirier JT, Rudin CM, Chen Y, Cripe TP, Bernhardt MB, Blaney SM. Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group. Pediatr Blood Cancer. 2015 May; 62(5):743-50. PMID: 25307519.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    31. Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51. PMID: 25257751.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    32. Su JM, Thompson P, Adesina A, Li XN, Kilburn L, Onar-Thomas A, Kocak M, Chyla B, McKeegan E, Warren KE, Goldman S, Pollack IF, Fouladi M, Chen A, Giranda V, Boyett J, Kun L, Blaney SM. A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report. Neuro Oncol. 2014 Dec; 16(12):1661-8. PMID: 24908656.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    33. Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, Martin S, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer. 2014 Sep; 61(9):1598-602. PMID: 24753394.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    34. Fouladi M, Perentesis JP, Phillips CL, Leary S, Reid JM, McGovern RM, Ingle AM, Ahern CH, Ames MM, Houghton P, Doyle LA, Weigel B, Blaney SM. A phase I trial of MK-2206 in children with refractory malignancies: A Children's Oncology Group study. 2014; 61(7):1246-1251.
    35. Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. 2014; 61(5):833-839.
    36. Thompson PA, Drissi R, Muscal JA, Panditharatna E, Fouladi M, Ingle AM, Ahern CH, Reid JM, Lin T, Weigel BJ, Blaney SM. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112). Clin Cancer Res. 2013 Dec 01; 19(23):6578-84. PMID: 24097866.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    37. Weigel B, Malempati S, Reid JM, Voss SD, Cho SY, Chen HX, Krailo M, Villaluna D, Adamson PC, Blaney SM. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6. PMID: 23956055.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    38. Glade Bender JL, Lee A, Reid JM, Baruchel S, Roberts T, Voss SD, Wu B, Ahern CH, Ingle AM, Harris P, Weigel BJ, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43. PMID: 23857966.
      Citations: 40     Fields:    Translation:HumansCTClinical Trials
    39. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Goldman S, Geyer JR, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Neurooncol. 2013 Sep; 114(2):173-9. PMID: 23836190.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    40. Liu Z, Zhao X, Mao H, Baxter PA, Huang Y, Yu L, Wadhwa L, Su JM, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Hurwitz RL, Lau CC, Chintagumpala M, Blaney SM, Li XN. Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor-based orthotopic xenograft mouse models of pediatric glioma. Neuro Oncol. 2013 Sep; 15(9):1173-85. PMID: 23658322.
      Citations: 30     Fields:    Translation:AnimalsCells
    41. Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, Rolland D, Balis FM, Maris JM, Weigel BJ, Ingle AM, Ahern C, Adamson PC, Blaney SM. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80. PMID: 23598171.
      Citations: 170     Fields:    Translation:HumansCTClinical Trials
    42. Kilburn LB, Kocak M, Schaedeli Stark F, Meneses-Lorente G, Brownstein C, Hussain S, Chintagumpala M, Thompson PA, Gururangan S, Banerjee A, Paulino AC, Kun L, Boyett JM, Blaney SM. Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas. Neuro Oncol. 2013 Jun; 15(6):759-66. PMID: 23592571.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    43. Hummel TR, Wagner L, Ahern C, Fouladi M, Reid JM, McGovern RM, Ames MM, Gilbertson RJ, Horton T, Ingle AM, Weigel B, Blaney SM. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2013 Sep; 60(9):1452-7. PMID: 23554030.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    44. Blaney SM, Tagen M, Onar-Thomas A, Berg SL, Gururangan S, Scorsone K, Su J, Goldman S, Kieran MW, Kun L, Boyett J, Stewart C. A phase-1 pharmacokinetic optimal dosing study of intraventricular topotecan for children with neoplastic meningitis: a Pediatric Brain Tumor Consortium study. Pediatr Blood Cancer. 2013 Apr; 60(4):627-32. PMID: 23002039.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    45. Mossé YP, Lipsitz E, Fox E, Teachey DT, Maris JM, Weigel B, Adamson PC, Ingle MA, Ahern CH, Blaney SM. Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study. Clin Cancer Res. 2012 Nov 01; 18(21):6058-64. PMID: 22988055.
      Citations: 39     Fields:    Translation:HumansCTClinical Trials
    46. Widemann BC, Kim A, Fox E, Baruchel S, Adamson PC, Ingle AM, Glade Bender J, Burke M, Weigel B, Stempak D, Balis FM, Blaney SM. A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report. Clin Cancer Res. 2012 Nov 01; 18(21):6011-22. PMID: 22962440.
      Citations: 44     Fields:    Translation:HumansCTClinical Trials
    47. Muscal JA, Thompson PA, Horton TM, Ingle AM, Ahern CH, McGovern RM, Reid JM, Ames MM, Espinoza-Delgado I, Weigel BJ, Blaney SM. A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatr Blood Cancer. 2013 Mar; 60(3):390-5. PMID: 22887890.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    48. Blaney SM, Kocak M, Gajjar A, Chintagumpala M, Merchant T, Kieran M, Pollack IF, Gururangan S, Geyer R, Phillips P, McLendon RE, Packer R, Goldman S, Banerjee A, Heideman R, Boyett JM, Kun L. Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001). J Neurooncol. 2012 Sep; 109(3):565-71. PMID: 22790443.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    49. Glade Bender J, Blaney SM, Borinstein S, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report. Clin Cancer Res. 2012 Sep 15; 18(18):5081-9. PMID: 22791883.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    50. Warwick AB, Malempati S, Krailo M, Melemed A, Gorlick R, Ames MM, Safgren SL, Adamson PC, Blaney SM. Phase 2 trial of pemetrexed in children and adolescents with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2013 Feb; 60(2):237-41. PMID: 22745043.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    51. Day ES, Zhang L, Thompson PA, Zawaski JA, Kaffes CC, Gaber MW, Blaney SM, West JL. Vascular-targeted photothermal therapy of an orthotopic murine glioma model. Nanomedicine (Lond). 2012 Aug; 7(8):1133-48. PMID: 22583571.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    52. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT, Reid JM, Schmechel S, Voss SD, Cho SY, Chen HX, Krailo MD, Adamson PC, Blaney SM. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62. PMID: 22184397.
      Citations: 75     Fields:    Translation:HumansCTClinical Trials
    53. DuBois SG, Shusterman S, Reid JM, Ingle AM, Ahern CH, Baruchel S, Glade-Bender J, Ivy P, Adamson PC, Blaney SM. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Cancer Chemother Pharmacol. 2012 Apr; 69(4):1021-7. PMID: 22179104.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    54. Baruchel S, Pappo A, Krailo M, Baker KS, Wu B, Villaluna D, Lee-Scott M, Adamson PC, Blaney SM. A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology Group. Eur J Cancer. 2012 Mar; 48(4):579-85. PMID: 22088484.
      Citations: 31     Fields:    Translation:HumansCTClinical Trials
    55. Potter SL, Berg S, Ingle AM, Krailo M, Adamson PC, Blaney SM. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer. 2012 Mar; 58(3):362-5. PMID: 21910214.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    56. McLendon RE, Adekunle A, Rajaram V, Koçak M, Blaney SM. Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. Arch Pathol Lab Med. 2011 Aug; 135(8):984-93. PMID: 21809989.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    57. Jakacki RI, Bouffet E, Adamson PC, Pollack IF, Ingle AM, Voss SD, Blaney SM. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro Oncol. 2011 Aug; 13(8):910-5. PMID: 21764821.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    58. Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study. Clin Cancer Res. 2011 Aug 01; 17(15):5113-22. PMID: 21690570.
      Citations: 38     Fields:    Translation:HumansCTClinical Trials
    59. Rajagopal MU, Hathout Y, MacDonald TJ, Kieran MW, Gururangan S, Blaney SM, Phillips P, Packer R, Gordish-Dressman H, Rood BR. Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study. Proteomics. 2011 Mar; 11(5):935-43. PMID: 21271676.
      Citations: 14     Fields:    Translation:HumansCells
    60. Aplenc R, Blaney SM, Strauss LC, Balis FM, Shusterman S, Ingle AM, Agrawal S, Sun J, Wright JJ, Adamson PC. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium. J Clin Oncol. 2011 Mar 01; 29(7):839-44. PMID: 21263099.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    61. Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol. 2011 Jan 20; 29(3):324-9. PMID: 21149652.
      Citations: 28     Fields:    Translation:HumansCTClinical Trials
    62. Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol. 2011 Jan 20; 29(3):316-23. PMID: 21149673.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    63. Su JM, Li XN, Thompson P, Ou CN, Ingle AM, Russell H, Lau CC, Adamson PC, Blaney SM. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report. Clin Cancer Res. 2011 Feb 01; 17(3):589-97. PMID: 21115653.
      Citations: 37     Fields:    Translation:HumansCellsCTClinical Trials
    64. Day ES, Thompson PA, Zhang L, Lewinski NA, Ahmed N, Drezek RA, Blaney SM, West JL. Nanoshell-mediated photothermal therapy improves survival in a murine glioma model. J Neurooncol. 2011 Aug; 104(1):55-63. PMID: 21110217.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    65. Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG. A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011 Aug; 57(2):275-82. PMID: 21671363.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    66. Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011 Jan; 13(1):14-27. PMID: 21075780.
      Citations: 23     Fields:    Translation:HumansAnimalsCells
    67. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Oct; 55(4):629-38. PMID: 20589651.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    68. Widemann BC, Arceci RJ, Jayaprakash N, Fox E, Zannikos P, Goodspeed W, Goodwin A, Wright JJ, Blaney SM, Adamson PC, Balis FM. Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011 Feb; 56(2):226-33. PMID: 20860038.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    69. Beaty O, Berg S, Blaney S, Malogolowkin M, Krailo M, Knight R, Schaiquevich P, Stewart C, Chen Z, Nelson M, Voss S, Ivy SP, Adamson PC. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2010 Sep; 55(3):440-5. PMID: 20658614.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    70. Fouladi M, Stewart CF, Blaney SM, Onar-Thomas A, Schaiquevich P, Packer RJ, Gajjar A, Kun LE, Boyett JM, Gilbertson RJ. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. J Clin Oncol. 2010 Sep 20; 28(27):4221-7. PMID: 20713864.
      Citations: 32     Fields:    Translation:HumansCellsCTClinical Trials
    71. Souid AK, Dubowy RL, Ingle AM, Conlan MG, Sun J, Blaney SM, Adamson PC. A pediatric phase I trial and pharmacokinetic study of ispinesib: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Dec 15; 55(7):1323-8. PMID: 20712019.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    72. Geyer JR, Stewart CF, Kocak M, Broniscer A, Phillips P, Douglas JG, Blaney SM, Packer RJ, Gururangan S, Banerjee A, Kieran MW, Kun LE, Gilbertson RJ, Boyett JM. A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas. Eur J Cancer. 2010 Dec; 46(18):3287-93. PMID: 20708924.
      Citations: 23     Fields:    Translation:HumansCTClinical Trials
    73. Berg SL, Winick N, Ingle AM, Adamson PC, Blaney SM. Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study. Pediatr Blood Cancer. 2010 Jul 15; 55(1):119-22. PMID: 20486176.
      Citations: 6     Fields:    Translation:Humans
    74. Fouladi M, Park JR, Stewart CF, Gilbertson RJ, Schaiquevich P, Sun J, Reid JM, Ames MM, Speights R, Ingle AM, Zwiebel J, Blaney SM, Adamson PC. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010 Aug 01; 28(22):3623-9. PMID: 20606092.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    75. Baxter PA, Thompson PA, McGuffey LM, Gibson BW, Dauser RC, Nuchtern JG, Shi C, Inloes R, Choy G, Redkar S, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates. Cancer Chemother Pharmacol. 2011 Apr; 67(4):809-12. PMID: 20563581.
      Citations:    Fields:    Translation:Animals
    76. Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr; 54(4):538-45. PMID: 20049936.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    77. Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, Man TK, Shu Q, Zhang YJ, Zhao XM, Su JM, Perlaky L, Dauser R, Chintagumpala M, Lau CC, Blaney SM, Rao PH, Leung HC, Li XN. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010 Jun; 12(6):580-94. PMID: 20511191.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    78. Jacobs S, Fox E, Krailo M, Hartley G, Navid F, Wexler L, Blaney SM, Goodwin A, Goodspeed W, Balis FM, Adamson PC, Widemann BC. Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group. Clin Cancer Res. 2010 Jan 15; 16(2):750-4. PMID: 20068084.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    79. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch AA, Blaney SM, Delaney SL, Hegde M, Berg SL. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. . 2009 Aug; 8(8):2232-42. PMID: 19671751.
      Citations:    
    80. Muscal JA, Thompson PA, Giranda VL, Dayton BD, Bauch J, Horton T, McGuffey L, Nuchtern JG, Dauser RC, Gibson BW, Blaney SM, Su JM. Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates. Cancer Chemother Pharmacol. 2010 Feb; 65(3):419-25. PMID: 19526240.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    81. McGregor LM, Spunt SL, Furman WL, Stewart CF, Schaiquevich P, Krailo MD, Speights R, Ivy P, Adamson PC, Blaney SM. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study. Cancer. 2009 Apr 15; 115(8):1765-75. PMID: 19170226.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    82. Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar; 52(3):346-50. PMID: 18989889.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    83. Kieran MW, Supko JG, Wallace D, Fruscio R, Poussaint TY, Phillips P, Pollack I, Packer R, Boyett JM, Blaney S, Banerjee A, Geyer R, Friedman H, Goldman S, Kun LE, Macdonald T. Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. Pediatr Blood Cancer. 2009 Feb; 52(2):169-76. PMID: 19065567.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    84. Kilburn LB, Bonate PL, Blaney SM, McGuffey L, Nuchtern JG, Dauser R, Thompson P, Gibson BW, Berg SL. Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates. Cancer Chemother Pharmacol. 2009 Jul; 64(2):335-40. PMID: 19043710.
      Citations:    Fields:    Translation:Animals
    85. Bomgaars L, Thompson P, Berg S, Serabe B, Aleksic A, Blaney S. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer. 2008 Oct; 51(4):504-8. PMID: 18561175.
      Citations: 5     Fields:    Translation:Humans
    86. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7. PMID: 18794549.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    87. Bradley KA, Pollack IF, Reid JM, Adamson PC, Ames MM, Vezina G, Blaney S, Ivy P, Zhou T, Krailo M, Reaman G, Mehta MP. Motexafin gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a Children's Oncology Group phase I study. Neuro Oncol. 2008 Oct; 10(5):752-8. PMID: 18715950.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    88. Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study. J Clin Oncol. 2008 Aug 01; 26(22):3756-62. PMID: 18669463.
      Citations: 66     Fields:    Translation:HumansCTClinical Trials
    89. Kim A, Fox E, Warren K, Blaney SM, Berg SL, Adamson PC, Libucha M, Byrley E, Balis FM, Widemann BC. Characteristics and outcome of pediatric patients enrolled in phase I oncology trials. Oncologist. 2008 Jun; 13(6):679-89. PMID: 18586923.
      Citations: 15     Fields:    Translation:Humans
    90. Jakacki RI, Yates A, Blaney SM, Zhou T, Timmerman R, Ingle AM, Flom L, Prados MD, Adamson PC, Pollack IF. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol. 2008 Aug; 10(4):569-76. PMID: 18497327.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    91. Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, McKnight T, Poussaint TY, Broniscer A, Blaney SM, Boyett JM, Kun LE. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol. 2008 Jun; 10(3):341-7. PMID: 18417739.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    92. Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, Antalffy BC, Baxter P, Perlaky L, Yang J, Dauser RC, Chintagumpala M, Blaney SM, Lau CC, Li XN. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 2008 Jun; 26(6):1414-24. PMID: 18403755.
      Citations: 71     Fields:    Translation:HumansAnimals
    93. Menon-Andersen D, Mondick JT, Jayaraman B, Thompson PA, Blaney SM, Bernstein M, Bond M, Champagne M, Fossler MJ, Barrett JS. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol. 2009 Jan; 63(2):229-38. PMID: 18398615.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    94. Jacob E, Scorsone K, Blaney SM, D'Argenio DZ, Berg SL. Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Pediatr Blood Cancer. 2008 Apr; 50(4):757-60. PMID: 17849472.
      Citations: 1     Fields:    Translation:HumansCells
    95. Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):549-53. PMID: 17941066.
      Citations: 9     Fields:    Translation:HumansCellsCTClinical Trials
    96. Langevin AM, Bernstein M, Kuhn JG, Blaney SM, Ivy P, Sun J, Chen Z, Adamson PC. A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Mar; 50(3):577-80. PMID: 17610262.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    97. Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Bernstein ML, Blaney SM, Mondick J. Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group. Cancer Chemother Pharmacol. 2008 Nov; 62(6):1027-37. PMID: 18278496.
      Citations: 5     Fields:    Translation:Humans
    98. Gururangan S, Turner CD, Stewart CF, O'Shaughnessy M, Kocak M, Poussaint TY, Phillips PC, Goldman S, Packer R, Pollack IF, Blaney SM, Karsten V, Gerson SL, Boyett JM, Friedman HS, Kun LE. Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study. Clin Cancer Res. 2008 Feb 15; 14(4):1124-30. PMID: 18281546.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    99. Bond M, Bernstein ML, Pappo A, Schultz KR, Krailo M, Blaney SM, Adamson PC. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2008 Feb; 50(2):254-8. PMID: 17262795.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    100. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405. PMID: 18202416.
      Citations: 83     Fields:    Translation:HumansCTClinical Trials
    101. Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 01; 25(31):4922-8. PMID: 17971589.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    102. Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Blood. 2008 Jan 15; 111(2):566-73. PMID: 17959855.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    103. Bomgaars LR, Bernstein M, Krailo M, Kadota R, Das S, Chen Z, Adamson PC, Blaney SM. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Oct 10; 25(29):4622-7. PMID: 17925558.
      Citations: 42     Fields:    Translation:HumansCTClinical Trials
    104. Bernardi RJ, Bomgaars L, Fox E, Balis FM, Egorin MJ, Lagattuta TF, Aikin A, Whitcomb P, Renbarger J, Lieberman FS, Berg SL, Blaney SM. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. 2008 Jul; 62(2):355-61. PMID: 17909804.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    105. Bernardi RJ, Lowery AR, Thompson PA, Blaney SM, West JL. Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines. J Neurooncol. 2008 Jan; 86(2):165-72. PMID: 17805488.
      Citations: 38     Fields:    Translation:HumansCells
    106. Jimeno A, Daw NC, Amador ML, Cusatis G, Kulesza P, Krailo M, Ingle AM, Blaney SM, Adamson P, Hidalgo M. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer. 2007 Sep; 49(3):352-7. PMID: 16425266.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    107. Kieran MW, Packer RJ, Onar A, Blaney SM, Phillips P, Pollack IF, Geyer JR, Gururangan S, Banerjee A, Goldman S, Turner CD, Belasco JB, Broniscer A, Zhu Y, Frank E, Kirschmeier P, Statkevich P, Yver A, Boyett JM, Kun LE. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study. J Clin Oncol. 2007 Jul 20; 25(21):3137-43. PMID: 17634493.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    108. Stapleton SL, Thompson PA, Ou CN, Berg SL, McGuffey L, Gibson B, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol. 2008 Apr; 61(4):647-52. PMID: 17541590.
      Citations: 6     Fields:    Translation:Animals
    109. Malempati S, Nicholson HS, Reid JM, Blaney SM, Ingle AM, Krailo M, Stork LC, Melemed AS, McGovern R, Safgren S, Ames MM, Adamson PC. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. J Clin Oncol. 2007 Apr 20; 25(12):1505-11. PMID: 17442992.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    110. Rheingold SR, Hogarty MD, Blaney SM, Zwiebel JA, Sauk-Schubert C, Chandula R, Krailo MD, Adamson PC. Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2007 Apr 20; 25(12):1512-8. PMID: 17442993.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    111. Weigel BJ, Blaney SM, Reid JM, Safgren SL, Bagatell R, Kersey J, Neglia JP, Ivy SP, Ingle AM, Whitesell L, Gilbertson RJ, Krailo M, Ames M, Adamson PC. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 15; 13(6):1789-93. PMID: 17363534.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    112. Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM. A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. Clin Cancer Res. 2007 Mar 01; 13(5):1516-22. PMID: 17332297.
      Citations: 51     Fields:    Translation:HumansCTClinical Trials
    113. Pollack IF, Jakacki RI, Blaney SM, Hancock ML, Kieran MW, Phillips P, Kun LE, Friedman H, Packer R, Banerjee A, Geyer JR, Goldman S, Poussaint TY, Krasin MJ, Wang Y, Hayes M, Murgo A, Weiner S, Boyett JM. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol. 2007 Apr; 9(2):145-60. PMID: 17293590.
      Citations: 71     Fields:    Translation:HumansCTClinical Trials
    114. Li XN, Shu Q, Su JM, Adesina AM, Wong KK, Perlaky L, Antalffy BA, Blaney SM, Lau CC. Differential expression of survivin splice isoforms in medulloblastomas. Neuropathol Appl Neurobiol. 2007 Feb; 33(1):67-76. PMID: 17239009.
      Citations: 9     Fields:    Translation:HumansCells
    115. Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, Camitta BM, Dreyer ZE, Bomgaars LR. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol. 2007 May; 59(6):847-53. PMID: 17136402.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    116. Fouladi M, Blaney SM, Poussaint TY, Freeman BB, McLendon R, Fuller C, Adesina AM, Hancock ML, Danks MK, Stewart C, Boyett JM, Gajjar A. Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer. 2006 Nov 01; 107(9):2291-7. PMID: 17019740.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    117. Hawkins DS, Bradfield S, Whitlock JA, Krailo M, Franklin J, Blaney SM, Adamson PC, Reaman G. Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2006 Nov; 47(6):790-4. PMID: 16435380.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    118. Berg SL, Brueckner C, Nuchtern JG, Dauser R, McGuffey L, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates. Cancer Chemother Pharmacol. 2007 May; 59(6):743-7. PMID: 16953392.
      Citations: 1     Fields:    Translation:Animals
    119. Stapleton S, Blaney S. New agents for intrathecal administration. Cancer Invest. 2006 Aug-Sep; 24(5):528-34. PMID: 16939963.
      Citations: 7     Fields:    Translation:HumansAnimals
    120. Fouladi M, Furman WL, Chin T, Freeman BB, Dudkin L, Stewart CF, Krailo MD, Speights R, Ingle AM, Houghton PJ, Wright J, Adamson PC, Blaney SM. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J Clin Oncol. 2006 Aug 01; 24(22):3678-85. PMID: 16877737.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    121. Shu Q, Antalffy B, Su JM, Adesina A, Ou CN, Pietsch T, Blaney SM, Lau CC, Li XN. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts. Clin Cancer Res. 2006 Aug 01; 12(15):4687-94. PMID: 16899619.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    122. Bomgaars LR, Megason GC, Pullen J, Langevin AM, Dale Weitman S, Hershon L, Kuhn JG, Bernstein M, Blaney SM. Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors. Pediatr Blood Cancer. 2006 Aug; 47(2):163-8. PMID: 16317728.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    123. Stapleton SL, Reid JM, Thompson PA, Ames MM, McGovern RM, McGuffey L, Nuchtern J, Dauser R, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Cancer Chemother Pharmacol. 2007 Mar; 59(4):461-6. PMID: 16855840.
      Citations: 12     Fields:    Translation:AnimalsCells
    124. Chintagumpala MM, Friedman HS, Stewart CF, Kepner J, McLendon RE, Modrich PL, McCluggage C, Burger P, Holmes E, Thompson S, Rutka J, Michalski J, Woo S, Blaney SM, Kun LE, Horowitz ME. A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group. J Neurooncol. 2006 Apr; 77(2):193-8. PMID: 16314955.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    125. Gururangan S, Petros WP, Poussaint TY, Hancock ML, Phillips PC, Friedman HS, Bomgaars L, Blaney SM, Kun LE, Boyett JM. Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004). Clin Cancer Res. 2006 Mar 01; 12(5):1540-6. PMID: 16533779.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    126. Widemann BC, Salzer WL, Arceci RJ, Blaney SM, Fox E, End D, Gillespie A, Whitcomb P, Palumbo JS, Pitney A, Jayaprakash N, Zannikos P, Balis FM. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas. J Clin Oncol. 2006 Jan 20; 24(3):507-16. PMID: 16421428.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    127. Bomgaars L, Kerr J, Berg S, Kuttesch J, Klenke R, Blaney SM. A phase I study of irinotecan administered on a weekly schedule in pediatric patients. Pediatr Blood Cancer. 2006 Jan; 46(1):50-5. PMID: 15768380.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    128. Li XN, Shu Q, Su JM, Perlaky L, Blaney SM, Lau CC. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. . 2005 Dec; 4(12):1912-22. PMID: 16373706.
      Citations:    
    129. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006 Jul; 58(1):13-23. PMID: 16292537.
      Citations: 34     Fields:    Translation:HumansCells
    130. Greenberg ML, Fisher PG, Freeman C, Korones DN, Bernstein M, Friedman H, Blaney S, Hershon L, Zhou T, Chen Z, Kretschmar C. Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study. Pediatr Blood Cancer. 2005 Oct 15; 45(5):644-8. PMID: 16110498.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    131. Daw NC, Furman WL, Stewart CF, Iacono LC, Krailo M, Bernstein ML, Dancey JE, Speights RA, Blaney SM, Croop JM, Reaman GH, Adamson PC. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005 Sep 01; 23(25):6172-80. PMID: 16135484.
      Citations: 32     Fields:    Translation:HumansCTClinical Trials
    132. Berg SL, Bonate PL, Nuchtern JG, Dauser R, McGuffey L, Bernacky B, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates. Clin Cancer Res. 2005 Aug 15; 11(16):5981-3. PMID: 16115942.
      Citations: 5     Fields:    Translation:Animals
    133. Adamson PC, Blaney SM. New approaches to drug development in pediatric oncology. Cancer J. 2005 Jul-Aug; 11(4):324-30. PMID: 16197722.
      Citations: 7     Fields:    Translation:Humans
    134. Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB. Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group. J Clin Oncol. 2005 May 20; 23(15):3376-82. PMID: 15908649.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    135. Blaney SM, Balis FM, Berg S, Arndt CA, Heideman R, Geyer JR, Packer R, Adamson PC, Jaeckle K, Klenke R, Aikin A, Murphy R, McCully C, Poplack DG. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. 2005 Mar 01; 23(7):1555-63. PMID: 15735131.
      Citations: 12     Fields:    Translation:HumansAnimalsCTClinical Trials
    136. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A. Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol. 2005 Mar 01; 23(7):1491-9. PMID: 15735125.
      Citations: 104     Fields:    Translation:Humans
    137. Horton TM, Blaney SM, Langevin AM, Kuhn J, Kamen B, Berg SL, Bernstein M, Weitman S. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study. Clin Cancer Res. 2005 Mar 01; 11(5):1884-9. PMID: 15756014.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    138. Blaney SM, Boyett J, Friedman H, Gajjar A, Geyer R, Horowtiz M, Hunt D, Kieran M, Kun L, Packer R, Phillips P, Pollack IF, Prados M, Heideman R. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J Clin Oncol. 2005 Jan 20; 23(3):525-31. PMID: 15659498.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    139. Lau L, Supko JG, Blaney S, Hershon L, Seibel N, Krailo M, Qu W, Malkin D, Jimeno J, Bernstein M, Baruchel S. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):672-7. PMID: 15701855.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    140. Neville KA, Blaney SM. Leptomeningeal cancer in the pediatric patient. Cancer Treat Res. 2005; 125:87-106. PMID: 16211885.
      Citations: 1     Fields:    Translation:Humans
    141. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, Camitta B, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia. 2005 Jan; 19(1):34-8. PMID: 15510203.
      Citations: 29     Fields:    Translation:Humans
    142. Wong KK, Chang YM, Tsang YT, Perlaky L, Su J, Adesina A, Armstrong DL, Bhattacharjee M, Dauser R, Blaney SM, Chintagumpala M, Lau CC. Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups. Cancer Res. 2005 Jan 01; 65(1):76-84. PMID: 15665281.
      Citations: 27     Fields:    Translation:HumansCells
    143. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, Berg SL, Krailo M, Adamson PC. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol. 2004 Dec 01; 22(23):4804-9. PMID: 15570082.
      Citations: 33     Fields:    Translation:HumansCTClinical Trials
    144. Chintagumpala M, Blaney SM, Bomgaars LR, Aleksic A, Kuttesch JF, Klenke RA, Berg SL. Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer. J Clin Oncol. 2004 Nov 01; 22(21):4394-400. PMID: 15514381.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    145. Zhang L, Plon SE, Nuchtern JG, Burlingame S, Blaney S, Rousseau R, Berg S. Cyclin D and cisplatin cytotoxicity in primary neuroblastoma cell lines. Anticancer Drugs. 2004 Oct; 15(9):883-8. PMID: 15457129.
      Citations: 2     Fields:    Translation:HumansCells
    146. Bomgaars L, Geyer JR, Franklin J, Dahl G, Park J, Winick NJ, Klenke R, Berg SL, Blaney SM. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol. 2004 Oct 01; 22(19):3916-21. PMID: 15459213.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    147. Neville K, Blaney S, Bernstein M, Thompson P, Adams D, Aleksic A, Berg S. Pharmacokinetics of O(6)-benzylguanine in pediatric patients with central nervous system tumors: a pediatric oncology group study. Clin Cancer Res. 2004 Aug 01; 10(15):5072-5. PMID: 15297409.
      Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
    148. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, Therrien M, Zoellner U, Blaney SM, Bernstein M. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004 Nov 01; 104(9):2655-60. PMID: 15231574.
      Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
    149. Berg SL, Aleksic A, McGuffey L, Dauser R, Nuchtern J, Bernacky B, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Aug; 54(2):127-30. PMID: 15150671.
      Citations: 3     Fields:    Translation:Animals
    150. Aquino VM, Weitman SD, Winick NJ, Blaney S, Furman WL, Kepner JL, Bonate P, Krailo M, Qu W, Bernstein M. Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clin Oncol. 2004 Apr 15; 22(8):1413-9. PMID: 15084615.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    151. Neville K, Parise RA, Thompson P, Aleksic A, Egorin MJ, Balis FM, McGuffey L, McCully C, Berg SL, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates. Clin Cancer Res. 2004 Apr 01; 10(7):2525-9. PMID: 15073132.
      Citations: 15     Fields:    Translation:AnimalsCells
    152. Berg SL, Stone J, Xiao JJ, Chan KK, Nuchtern J, Dauser R, McGuffey L, Thompson P, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jul; 54(1):85-8. PMID: 15042312.
      Citations: 14     Fields:    Translation:Animals
    153. Adamson PC, Blaney SM, Widemann BC, Kitchen B, Murphy RF, Hannah AL, Cropp GF, Patel M, Gillespie AF, Whitcomb PG, Balis FM. Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101. Cancer Chemother Pharmacol. 2004 Jun; 53(6):482-8. PMID: 14999430.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    154. Thompson PA, Berg SL, Aleksic A, Kerr JZ, McGuffey L, Dauser R, Nuchtern JG, Hausheer F, Blaney SM. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jun; 53(6):527-32. PMID: 14997342.
      Citations: 3     Fields:    Translation:Animals
    155. Li XN, Parikh S, Shu Q, Jung HL, Chow CW, Perlaky L, Leung HC, Su J, Blaney S, Lau CC. Phenylbutyrate and phenylacetate induce differentiation and inhibit proliferation of human medulloblastoma cells. Clin Cancer Res. 2004 Feb 01; 10(3):1150-9. PMID: 14871995.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    156. Renbarger J, Aleksic A, McGuffey L, Dauser R, Berg S, Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of SU5416 after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2004 Jan; 53(1):39-42. PMID: 14551735.
      Citations: 5     Fields:    Translation:Animals
    157. Thompson P, Balis F, Serabe BM, Berg S, Adamson P, Klenke R, Aiken A, Packer R, Murry DJ, Jakacki R, Blaney SM. Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer. Cancer Chemother Pharmacol. 2003 Nov; 52(5):417-23. PMID: 12879279.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    158. Langevin AM, Weitman SD, Kuhn JG, Weintraub ST, Baruchel S, Furman W, Bernstein M, Blaney S, Vietti T. Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003 Jul; 25(7):526-33. PMID: 12847318.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    159. Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003 Jul; 25(7):539-42. PMID: 12847320.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    160. Souid AK, Dubowy RL, Blaney SM, Hershon L, Sullivan J, McLeod WD, Bernstein ML. Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin Cancer Res. 2003 Feb; 9(2):703-10. PMID: 12576438.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    161. Blaney SM, Heideman R, Berg S, Adamson P, Gillespie A, Geyer JR, Packer R, Matthay K, Jaeckle K, Cole D, Kuttesch N, Poplack DG, Balis FM. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol. 2003 Jan 01; 21(1):143-7. PMID: 12506183.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    162. Houghton PJ, Adamson PC, Blaney S, Fine HA, Gorlick R, Haber M, Helman L, Hirschfeld S, Hollingshead MG, Israel MA, Lock RB, Maris JM, Merlino G, Patterson W, Reynolds CP, Shannon K, Yu A, Yu J, Smith MA. Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res. 2002 Dec; 8(12):3646-57. PMID: 12473573.
      Citations: 19     Fields:    Translation:HumansAnimals
    163. McGuffey LH, McCully CL, Bernacky BJ, Blaney SM. Incorporation of an enrichment program into a study protocol involving long-term restraint in macaques. Lab Anim (NY). 2002 Nov; 31(10):37-9. PMID: 12404014.
      Citations: 2     Fields:    Translation:Animals
    164. Egorin MJ, Zuhowski EG, McCully CM, Blaney SM, Kerr JZ, Berg SL, Balis FM. Pharmacokinetics of intrathecal gemcitabine in nonhuman primates. Clin Cancer Res. 2002 Jul; 8(7):2437-42. PMID: 12114450.
      Citations: 3     Fields:    Translation:Animals
    165. Packer RJ, Biegel JA, Blaney S, Finlay J, Geyer JR, Heideman R, Hilden J, Janss AJ, Kun L, Vezina G, Rorke LB, Smith M. Atypical teratoid/rhabdoid tumor of the central nervous system: report on workshop. J Pediatr Hematol Oncol. 2002 Jun-Jul; 24(5):337-42. PMID: 12142780.
      Citations: 57     Fields:    Translation:HumansCells
    166. Marina NM, Cochrane D, Harney E, Zomorodi K, Blaney S, Winick N, Bernstein M, Link MP. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res. 2002 Feb; 8(2):413-8. PMID: 11839657.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    167. Murry DJ, Cherrick I, Salama V, Berg S, Bernstein M, Kuttesch N, Blaney SM. Influence of phenytoin on the disposition of irinotecan: a case report. J Pediatr Hematol Oncol. 2002 Feb; 24(2):130-3. PMID: 11990699.
      Citations: 8     Fields:    Translation:Humans
    168. Goldstein SL, Murry DJ, May S, Aleksic A, Sowinski KM, Blaney S. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. Pediatr Nephrol. 2001 Dec; 16(12):1015-8. PMID: 11793091.
      Citations: 2     Fields:    Translation:Humans
    169. Chintagumpala M, Berg S, Blaney SM. Treatment controversies in medulloblastoma. Curr Opin Oncol. 2001 May; 13(3):154-9. PMID: 11307057.
      Citations: 3     Fields:    Translation:Humans
    170. Berg S, Serabe B, Aleksic A, Bomgaars L, McGuffey L, Dauser R, Durfee J, Nuchtern J, Blaney S. Pharmacokinetics and cerebrospinal fluid penetration of phenylacetate and phenylbutyrate in the nonhuman primate. Cancer Chemother Pharmacol. 2001 May; 47(5):385-90. PMID: 11391852.
      Citations: 11     Fields:    Translation:Animals
    171. Kerr JZ, Berg SL, Dauser R, Nuchtern J, Egorin MJ, McGuffey L, Aleksic A, Blaney S. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates. Cancer Chemother Pharmacol. 2001 May; 47(5):411-4. PMID: 11391856.
      Citations: 4     Fields:    Translation:Animals
    172. Kerr JZ, Berg S, Blaney SM. Intrathecal chemotherapy. Crit Rev Oncol Hematol. 2001 Mar; 37(3):227-36. PMID: 11248578.
      Citations: 17     Fields:    Translation:Humans
    173. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, Camitta B, Hastings C, Blaney SM, Relling MV, Reaman GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. J Clin Oncol. 2001 Feb 01; 19(3):697-704. PMID: 11157020.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    174. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L, Bernstein M. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res. 2001 Jan; 7(1):32-7. PMID: 11205914.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    175. Bomgaars L, Berg SL, Blaney SM. The development of camptothecin analogs in childhood cancers. Oncologist. 2001; 6(6):506-16. PMID: 11743213.
      Citations: 10     Fields:    Translation:Humans
    176. Berg SL, Blaney SM, Sullivan J, Bernstein M, Dubowy R, Harris MB. Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol. 2000 Nov-Dec; 22(6):506-9. PMID: 11132217.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    177. Nuchtern J, McGuffey L, Durfee J, Dauser R, Blaney SM. Modified procedure for implantation of subcutaneous central venous access devices in macaques (Macaca mulatta). Comp Med. 2000 Oct; 50(5):486-9. PMID: 11099129.
      Citations:    Fields:    Translation:Animals
    178. Murry DJ, Blaney SM. Clinical pharmacology of encapsulated sustained-release cytarabine. Ann Pharmacother. 2000 Oct; 34(10):1173-8. PMID: 11054987.
      Citations: 15     Fields:    Translation:HumansAnimals
    179. Blaney SM, Poplack DG. Neoplastic meningitis: diagnosis and treatment considerations. Med Oncol. 2000 Aug; 17(3):151-62. PMID: 10962524.
      Citations: 7     Fields:    Translation:Humans
    180. Riva L, Blaney SM, Dauser R, Nuchtern JG, Durfee J, McGuffey L, Berg SL. Pharmacokinetics and cerebrospinal fluid penetration of CI-994 (N-acetyldinaline) in the nonhuman primate. Clin Cancer Res. 2000 Mar; 6(3):994-7. PMID: 10741726.
      Citations: 10     Fields:    Translation:Animals
    181. Balis FM, Blaney SM, McCully CL, Bacher JD, Murphy RF, Poplack DG. Methotrexate distribution within the subarachnoid space after intraventricular and intravenous administration. Cancer Chemother Pharmacol. 2000; 45(3):259-64. PMID: 10663645.
      Citations: 11     Fields:    Translation:Animals
    182. Bernstein ML, Baruchel S, Devine S, Markoglou N, Wainer IW, Williams M, Blaney S, Moghrabi A, Winick N, Vietti T. Phase I and pharmacokinetic study of CI-980 in recurrent pediatric solid tumor cases: a Pediatric Oncology Group study. J Pediatr Hematol Oncol. 1999 Nov-Dec; 21(6):494-500. PMID: 10598660.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    183. Kitchen BJ, Moser A, Lowe E, Balis FM, Widemann B, Anderson L, Strong J, Blaney SM, Berg SL, O'Brien M, Adamson PC. Thioguanine administered as a continuous intravenous infusion to pediatric patients is metabolized to the novel metabolite 8-hydroxy-thioguanine. J Pharmacol Exp Ther. 1999 Nov; 291(2):870-4. PMID: 10525111.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    184. Seibel NL, Blaney SM, O'Brien M, Krailo M, Hutchinson R, Mosher RB, Balis FM, Reaman GH. Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. Clin Cancer Res. 1999 Apr; 5(4):733-7. PMID: 10213206.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    185. Serabe BM, Murry DJ, Dauser R, Nuchtern J, Durfee J, McGuffey L, Berg S, Blaney SM. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemother Pharmacol. 1999; 43(5):415-8. PMID: 10100598.
      Citations: 7     Fields:    Translation:Animals
    186. Langevin AM, Casto DT, Thomas PJ, Weitman SD, Kretschmar C, Grier H, Pratt C, Dubowy R, Bernstein M, Blaney S, Vietti T. Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. J Clin Oncol. 1998 Jul; 16(7):2494-9. PMID: 9667269.
      Citations: 2     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    187. Blaney SM, Poplack DG. New cytotoxic drugs for intrathecal administration. J Neurooncol. 1998 Jun-Jul; 38(2-3):219-23. PMID: 9696375.
      Citations: 13     Fields:    Translation:Humans
    188. Parikh SH, Chintagumpala M, Hicks MJ, Trautwein LM, Blaney S, Minifee P, Woo SY. Clear cell sarcoma of the kidney: an unusual presentation and review of the literature. J Pediatr Hematol Oncol. 1998 Mar-Apr; 20(2):165-8. PMID: 9544171.
      Citations: 2     Fields:    Translation:Humans
    189. Blaney SM, Needle MN, Gillespie A, Sato JK, Reaman GH, Berg SL, Adamson PC, Krailo MD, Bleyer WA, Poplack DG, Balis FM. Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin Cancer Res. 1998 Feb; 4(2):357-60. PMID: 9516923.
      Citations: 13     Fields:    Translation:HumansCTClinical Trials
    190. Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol. 1998 Jan; 16(1):181-6. PMID: 9440741.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    191. Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Cancer Chemother Pharmacol. 1998; 41(6):464-8. PMID: 9554590.
      Citations: 9     Fields:    Translation:Animals
    192. Adamson PC, Reaman G, Finklestein JZ, Feusner J, Berg SL, Blaney SM, O'Brien M, Murphy RF, Balis FM. Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer. J Clin Oncol. 1997 Nov; 15(11):3330-7. PMID: 9363862.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    193. Blaney SM, Seibel NL, O'Brien M, Reaman GH, Berg SL, Adamson PC, Poplack DG, Krailo MD, Mosher R, Balis FM. Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol. 1997 Apr; 15(4):1538-43. PMID: 9193350.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    194. Blaney SM, Phillips PC, Packer RJ, Heideman RL, Berg SL, Adamson PC, Allen JC, Sallan SE, Jakacki RI, Lange BJ, Reaman GH, Horowitz ME, Poplack DG, Balis FM. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer. 1996 Aug 01; 78(3):527-31. PMID: 8697400.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    195. Blaney SM, Poplack DG. Pharmacologic strategies for the treatment of meningeal malignancy. Invest New Drugs. 1996; 14(1):69-85. PMID: 8880395.
      Citations: 1     Fields:    Translation:Humans
    196. Blaney SM, Poplack DG. Central nervous system leukemia. Curr Opin Oncol. 1996 Jan; 8(1):13-9. PMID: 8868094.
      Citations: 1     Fields:    Translation:Humans
    197. Ho PT, Zimmerman K, Wexler LH, Blaney S, Jarosinski P, Weaver-McClure L, Izraeli S, Balis FM. A prospective evaluation of ifosfamide-related nephrotoxicity in children and young adults. Cancer. 1995 Dec 15; 76(12):2557-64. PMID: 8625085.
      Citations: 15     Fields:    Translation:Humans
    198. Blaney SM, Daniel MJ, Harker AJ, Godwin K, Balis FM. Pharmacokinetics of lamivudine and BCH-189 in plasma and cerebrospinal fluid of nonhuman primates. Antimicrob Agents Chemother. 1995 Dec; 39(12):2779-82. PMID: 8593019.
      Citations: 20     Fields:    Translation:Animals
    199. Adamson PC, Balis FM, Belasco JE, Lange B, Berg SL, Blaney SM, Craig C, Poplack DG. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer. Cancer Res. 1995 Sep 15; 55(18):4069-72. PMID: 7664282.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    200. Blaney SM, Poplack DG, Godwin K, McCully CL, Murphy R, Balis FM. Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration. J Clin Oncol. 1995 Jan; 13(1):177-9. PMID: 7799017.
      Citations: 13     Fields:    Translation:Animals
    201. Blaney SM, Cole DE, Godwin K, Sung C, Poplack DG, Balis FM. Intrathecal administration of topotecan in nonhuman primates. Cancer Chemother Pharmacol. 1995; 36(2):121-4. PMID: 7767947.
      Citations: 15     Fields:    Translation:Animals
    202. Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Res. 1994 Oct 01; 54(19):5118-22. PMID: 7923128.
      Citations: 22     Fields:    Translation:Animals
    203. Izraeli S, Adamson PC, Blaney SM, Balis FM. Acute pancreatitis after ifosfamide therapy. Cancer. 1994 Sep 01; 74(5):1627-8. PMID: 8062195.
      Citations: 5     Fields:    Translation:Humans
    204. Blaney SM, Grem JL, Balis FM, Cole DE, Adamson PC, Poplack DG. Mechanism of resistance to cyclopentenyl cytosine (CPE-C) in Molt-4 lymphoblasts. Biochem Pharmacol. 1993 Apr 06; 45(7):1493-501. PMID: 8471071.
      Citations: 1     Fields:    Translation:HumansCells
    205. Blaney SM, Balis FM, Cole DE, Craig C, Reid JM, Ames MM, Krailo M, Reaman G, Hammond D, Poplack DG. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 1993 Mar 01; 53(5):1032-6. PMID: 8439950.
      Citations: 21     Fields:    Translation:HumansCTClinical Trials
    206. Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Res. 1993 Feb 15; 53(4):725-7. PMID: 8428353.
      Citations: 21     Fields:    Translation:AnimalsCells
    207. Blaney SM, Smith MA, Grem JL. Doxorubicin: role in the treatment of osteosarcoma. Cancer Treat Res. 1993; 62:55-73. PMID: 8096760.
      Citations: 2     Fields:    Translation:Humans
    208. Blaney SM, Balis FM, Grem J, Cole DE, Adamson PC, Poplack DG. Modulation of the cytotoxic effect of cyclopentenylcytosine by its primary metabolite, cyclopentenyluridine. Cancer Res. 1992 Jun 15; 52(12):3503-5. PMID: 1596909.
      Citations: 1     Fields:    Translation:HumansCells
    209. Balis FM, Pizzo PA, Butler KM, Hawkins ME, Brouwers P, Husson RN, Jacobsen F, Blaney SM, Gress J, Jarosinski P, et al. Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children. J Infect Dis. 1992 Jan; 165(1):99-104. PMID: 1727902.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    210. Balis FM, Blaney SM, Poplack DG. Antiretroviral drug development and clinical pharmacology. Pediatr Infect Dis J. 1991 Nov; 10(11):849-57. PMID: 1661004.
      Citations:    Fields:    Translation:HumansAnimals
    211. Blaney SM, Balis FM, Poplack DG. Current pharmacological treatment approaches to central nervous system leukaemia. Drugs. 1991 May; 41(5):702-16. PMID: 1712705.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    212. Blaney SM, Balis FM, Poplack DG. Pharmacologic approaches to the treatment of meningeal malignancy. Oncology (Williston Park). 1991 May; 5(5):107-16; discussion 123, 127. PMID: 1831994.
      Citations: 8     Fields:    Translation:Humans
    213. Blaney SM, Balis FM, Hegedus L, Heideman RL, McCully C, Murphy RF, Kelley JA, Poplack DG. Pharmacokinetics and metabolism of cyclopentenyl cytosine in nonhuman primates. Cancer Res. 1990 Dec 15; 50(24):7915-9. PMID: 2253232.
      Citations: 3     Fields:    Translation:AnimalsCells
    BLANEY's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (632)
    Explore
    _
    Co-Authors (36)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _